Literature DB >> 24176397

Antiproliferative activities and SAR studies of substituted anthraquinones and 1,4-naphthoquinones.

Deepak Bhasin1, Jonathan P Etter, Somsundaram N Chettiar, May Mok, Pui-Kai Li.   

Abstract

STAT3 is constitutively active in a large variety of cancers. The search for STAT3 inhibitors led to the discoveries of LLLs 3 and 12, which are substituted anthraquinones. LLL12 is an extremely potent compound that exhibits high levels of antiproliferative activity. Herein the synthesis and evaluation of compounds containing either an anthraquinone or 1,4-naphthoquinone moiety are reported. Analogs were evaluated in several cancer cell lines. Interestingly, it was found that the anthraquinones did not follow the same trends as the 1,4-naphthoquinones in regards to potency. LLL12, which contains a sulfonamide at position 1, was found to be the most potent of the anthraquinones. In contrast, the methyl ketone and methyl ester derivatives (LLLs 3.1 and 5.1) were found to be the most potent of the 1,4-naphthoquinones. Selected 1,4-naphthoquinones were also evaluated in the STAT3 fluorescence polarization assay in order to evaluate their abilities to bind to the STAT3 SH2 domain. They were found to have similar affinities, and their activities suggest that STAT3 is one of their molecular targets.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  LLL12; LLL3; STAT3 inhibitor

Mesh:

Substances:

Year:  2013        PMID: 24176397     DOI: 10.1016/j.bmcl.2013.09.098

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  5 in total

Review 1.  Journey of anthraquinones as anticancer agents - a systematic review of recent literature.

Authors:  M Shaheer Malik; Reem I Alsantali; Rabab S Jassas; Abdulrahman A Alsimaree; Riyaz Syed; Meshari A Alsharif; Kulkarni Kalpana; Moataz Morad; Ismail I Althagafi; Saleh A Ahmed
Journal:  RSC Adv       Date:  2021-11-05       Impact factor: 4.036

2.  Targeting mitochondria in cancer therapy could provide a basis for the selective anti-cancer activity.

Authors:  Dmitri Rozanov; Anton Cheltsov; Aaron Nilsen; Christopher Boniface; Isaac Forquer; James Korkola; Joe Gray; Jeffrey Tyner; Cristina E Tognon; Gordon B Mills; Paul Spellman
Journal:  PLoS One       Date:  2019-03-25       Impact factor: 3.240

3.  Ionically Crosslinked Chitosan Membranes Used as Drug Carriers for Cancer Therapy Application.

Authors:  Alecsandra Ferreira Tomaz; Sandra Maria Sobral de Carvalho; Rossemberg Cardoso Barbosa; Suédina M L Silva; Marcos Antônio Sabino Gutierrez; Antônio Gilson B de Lima; Marcus Vinícius L Fook
Journal:  Materials (Basel)       Date:  2018-10-20       Impact factor: 3.623

Review 4.  The diverse mechanisms and anticancer potential of naphthoquinones.

Authors:  Carolina Escardó Pereyra; Rafael Ferreira Dantas; Sabrina Baptista Ferreira; Luciano Pinho Gomes; Floriano Paes Silva-Jr
Journal:  Cancer Cell Int       Date:  2019-08-02       Impact factor: 5.722

5.  Evidence That the Anti-Inflammatory Effect of Rubiadin-1-methyl Ether Has an Immunomodulatory Context.

Authors:  Eduarda Talita Bramorski Mohr; Marcus Vinicius Pereira Dos Santos Nascimento; Júlia Salvan da Rosa; Guilherme Nicácio Vieira; Iara Fabricia Kretzer; Louis Pergaud Sandjo; Eduardo Monguilhott Dalmarco
Journal:  Mediators Inflamm       Date:  2019-11-03       Impact factor: 4.711

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.